



Press release | Lund 2026-09-08

Coegin Pharma reports strong clinical results for Follicopeptide® in eyelashes – statistically significant increase in eyelash length confirmed

Coegin Pharma AB ("Coegin" or the "Company") today announces encouraging results from a completed 56-day clinical study evaluating Follicopeptide® Lash Gel Serum for eyelashes. Visible effects were reported early, with almost one-third of participants experiencing visible results already within two weeks of once-daily use, followed by a substantial increase after four weeks. The early participant experience was subsequently supported by objective measurements demonstrating a statistically significant increase in eyelash length after both 42 and 56 days, confirmed by two separate instrumental measurement methods. Together with excellent tolerability demonstrated under ophthalmological control, the new clinical findings are consistent with the positive results from the eyelash panel testing communicated earlier. Coegin assesses that the combined results significantly strengthen the evidence and commercial potential of Follicopeptide® in the global eyelash category.

The clinical study

The study was conducted by independent testing laboratory J.S. Hamilton Poland in accordance with applicable industry standards and Cosmetics Europe guidelines for cosmetic efficacy evaluation and claim substantiation. The study included 22 participants and demonstrated statistically significant changes in eyelash length. Participants used Follicopeptide® Lash Gel Serum once daily for 56 days, with efficacy evaluated through participant assessments and two objective instrumental measurement methods.

Visible effects reported already within two weeks

One of the most encouraging findings was how early participants began noticing a difference. Almost one-third reported visible effects within only two weeks of use, with a substantial increase in participants experiencing visible results after four weeks.

The positive experience continued throughout the study. After 56 days, positive effects were reported across all six evaluated efficacy parameters: eyelash length, thickness, density and strength, improved overall appearance and reduced eyelash loss. The independent evaluation concluded that all six efficacy parameters were confirmed under the study conditions.

Coegin Pharma AB

c/o Medicon Village


223 81 Lund, Sweden

Registration number

559078-0465

coeginpharma.com

info@coeginpharma.com





Early experience followed by statistically significant increase in eyelash length

The early participant-reported effects were subsequently supported by objective instrumental measurements.

By Day 42, the increase in objectively measured eyelash length had become statistically significant, and statistical significance was maintained at Day 56. Importantly, the finding was confirmed using both digital caliper measurements and VISIA® clinical imaging.

The independent laboratory concluded that Follicopeptide® Lash Gel Serum significantly improved eyelash length after both 42 and 56 days of regular use under the study conditions.

"The combination of early visible effects reported by participants and statistically significant instrumental results makes these findings particularly exciting. Almost one-third of participants experienced visible effects already within two weeks, and with continued use we see a statistically significant increase in eyelash length, confirmed by two separate measurement methods," says Jens Eriksson, CEO of Coegin Pharma. "Together with the excellent tolerability around sensitive eyes, this represents an important step for Follicopeptide."

Excellent tolerability supports prostaglandin-free opportunity

In a complementary evaluation under ophthalmological control, no negative symptoms or sensations indicative of intolerance were reported during regular use.

Follicopeptide® is a prostaglandin-free peptide technology. Coegin believes the combination of early perceived effects, statistically significant improvement in eyelash length and excellent eye-area tolerability creates an attractive opportunity for the development of a new generation of high-performance eyelash products.

"We see a significant commercial opportunity for eyelash innovation that combines convincing performance with excellent tolerability around the eyes. We believe Follicopeptide has the potential to become an important prostaglandin-free alternative," says Jens Eriksson. "The new clinical results significantly strengthen our proposition in ongoing and future discussions with international beauty companies."

Coegin Pharma AB

c/o Medicon Village

223 81 Lund, Sweden

Registration number

559078-0465

coeginpharma.com

info@coeginpharma.com





Strengthens the broader commercial potential of Follicopeptide®

Follicopeptide® originates from extensive clinical research in scalp hair and is already being commercialized for hair thinning through Coegin's own VEXIENNE® brand and selected commercial partners. The new eyelash results add important clinical evidence from a distinctly different hair application and strengthen Coegin's strategy to expand Follicopeptide® across scalp hair, eyelashes and eyebrows.

"This is much bigger than an eyelash serum. We are building a proprietary peptide technology platform with potential across several major hair and beauty categories. The new clinical evidence substantially strengthens our ambition to establish the technology globally across hair, lashes and brows," says Jens Eriksson.

Coegin is preparing the first Follicopeptide®-based eyelash product for commercialization under VEXIENNE® and intends to use the new clinical data to accelerate ongoing and new discussions with international cosmetic companies.

For further information, please contact:

Jens Eriksson, CEO, or Lars B. Rasmussen, CFO

Email: info@coeginpharma.com

About Coegin Pharma

Coegin Pharma is a Swedish innovation company developing and commercializing advanced cosmetic technologies for hair and skin. The company's flagship innovation, Follicopeptide®, is a patented, clinically developed peptide technology targeting hair thinning. It is currently being introduced globally through selected partners and the company's own brand platform. In parallel, Coegin is also developing NPP-4, a next-generation cosmetic peptide innovation designed to enhance skin tone without UV exposure or chemicals.

With scalable in-house production, established intellectual property, and a flexible commercial model, Coegin Pharma is positioned to bring differentiated, science-based products to the global cosmetics market.

Coegin Pharma's share is listed on the NGM Growth Market and dual-listed on Börse Stuttgart. The company is headquartered in Lund, Sweden.

For more information, including company updates and social media links, visit coeginpharma.com

Coegin Pharma AB

c/o Medicon Village

223 81 Lund, Sweden

Registration number

559078-0465

coeginpharma.com

info@coeginpharma.com

